甘氨酰环素GAR-936对革兰氏阳性菌的体外活性。
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
作者信息
Boucher H W, Wennersten C B, Eliopoulos G M
机构信息
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
出版信息
Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9. doi: 10.1128/AAC.44.8.2225-2229.2000.
Abstract
The in vitro activities of GAR-936, the 9-t-butylglycylamido derivative of minocycline, were compared with those of doxycycline, minocycline, and tetracycline against 527 gram-positive clinical isolates. GAR-936 inhibited all strains, including those resistant to other tetracyclines, at concentrations of </=2 microg/ml, except two strains of JK diphtheroids for which the MIC was 4 microg/ml.
摘要
将米诺环素的9-叔丁基甘氨酰胺衍生物GAR-936与强力霉素、米诺环素和四环素对527株革兰氏阳性临床分离株的体外活性进行了比较。GAR-936在浓度≤2微克/毫升时能抑制所有菌株，包括那些对其他四环素耐药的菌株，但有两株JK类白喉杆菌的最低抑菌浓度为4微克/毫升。
相似文献
1
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.甘氨酰环素GAR-936对革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9. doi: 10.1128/AAC.44.8.2225-2229.2000.
2
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.新型甘氨酰环素GAR-936对1203株近期临床分离细菌的抗菌活性及抗菌谱
Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36. doi: 10.1016/s0732-8893(99)00092-9.
3
In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.针对耐抗生素革兰氏阳性血流感染分离株和产超广谱β-内酰胺酶菌株测试GAR-936的体外抗菌活性。
Diagn Microbiol Infect Dis. 2001 Aug;40(4):173-7. doi: 10.1016/s0732-8893(01)00269-3.
4
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.新型甘氨酰环素替加环素对从拉丁美洲分离出的1326株临床细菌菌株的体外活性。
Braz J Infect Dis. 2005 Oct;9(5):348-56. doi: 10.1590/s1413-86702005000500001. Epub 2006 Jan 6.
5
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.替加环素（GAR-936）针对11859株近期与社区获得性呼吸道感染及革兰氏阳性皮肤感染相关的临床分离菌株的体外活性。
Diagn Microbiol Infect Dis. 2004 Jul;49(3):201-9. doi: 10.1016/j.diagmicrobio.2004.03.002.
6
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).新型甘氨酰环素（米诺环素的9-叔丁基甘氨酰胺衍生物，GAR-936）的体外和体内抗菌活性
Antimicrob Agents Chemother. 1999 Apr;43(4):738-44. doi: 10.1128/AAC.43.4.738.
7
Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.新型甘氨酰环素类抗菌剂GAR-936的临床前药理学
Pharmacotherapy. 2000 Sep;20(9 Pt 2):219S-223S; discussion 224S-228S. doi: 10.1592/phco.20.14.219s.35046.
8
Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.GAR-936对需氧和厌氧动物及人类咬伤伤口病原体的体外比较活性。
Antimicrob Agents Chemother. 2000 Oct;44(10):2747-51. doi: 10.1128/AAC.44.10.2747-2751.2000.
9
Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.甘氨酰环素替加环素（原GAR-936）与四环素、米诺环素和多西环素对非结核分枝杆菌分离株的体外活性比较。
Antimicrob Agents Chemother. 2002 Oct;46(10):3164-7. doi: 10.1128/AAC.46.10.3164-3167.2002.
10
Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.将新型甘氨酰环素GAR-936与其他九种药物针对青霉素敏感和耐药肺炎球菌的抗肺炎球菌活性进行比较。
Antimicrob Agents Chemother. 2000 Apr;44(4):1085-8. doi: 10.1128/AAC.44.4.1085-1088.2000.
引用本文的文献
1
Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients.重症肝功能损害患者的替加环素给药策略
Antibiotics (Basel). 2022 Apr 3;11(4):479. doi: 10.3390/antibiotics11040479.
2
Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation of Study.67例感染患者替加环素的治疗药物监测及一项研究的群体药代动力学/微生物学评价
Front Microbiol. 2021 Jun 16;12:678165. doi: 10.3389/fmicb.2021.678165. eCollection 2021.
3
Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx).替加环素在通过最大肝功能试验（LiMAx）定义的肝功能衰竭重症患者中的药代动力学。
Ann Intensive Care. 2020 Aug 4;10(1):106. doi: 10.1186/s13613-020-00707-2.
4
Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.用于治疗婴儿、儿童和成人耐甲氧西林金黄色葡萄球菌感染的近期批准药物的药代动力学和安全性。
Expert Rev Clin Pharmacol. 2014 May;7(3):327-40. doi: 10.1586/17512433.2014.909281. Epub 2014 Apr 9.
5
2013 WSES guidelines for management of intra-abdominal infections.2013 WSES 腹腔内感染管理指南。
World J Emerg Surg. 2013 Jan 8;8(1):3. doi: 10.1186/1749-7922-8-3.
6
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.WSES 共识会议：腹腔内感染一线治疗管理指南。
World J Emerg Surg. 2011 Jan 13;6:2. doi: 10.1186/1749-7922-6-2.
7
A focus on intra-abdominal infections.关注腹腔内感染。
World J Emerg Surg. 2010 Mar 19;5:9. doi: 10.1186/1749-7922-5-9.
8
Newer antibacterial drugs for a new century.新世纪的新型抗菌药物。
Expert Opin Investig Drugs. 2010 Feb;19(2):215-34. doi: 10.1517/13543780903505092.
9
In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.替加环素及其他10种抗菌药物对非色素沉着快速生长分枝杆菌的体外活性
Antimicrob Agents Chemother. 2008 Nov;52(11):4184-6. doi: 10.1128/AAC.00695-08. Epub 2008 Aug 25.
10
Novel paradigms for drug discovery: computational multitarget screening.药物发现的新范式：计算多靶点筛选
Trends Pharmacol Sci. 2008 Feb;29(2):62-71. doi: 10.1016/j.tips.2007.11.007. Epub 2008 Jan 10.
本文引用的文献
1
Determinants of vancomycin use in adult intensive care units in 41 United States hospitals.美国41家医院成人重症监护病房中万古霉素使用的决定因素。
Clin Infect Dis. 1999 May;28(5):1119-25. doi: 10.1086/514752.
2
Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary.医院抗生素处方集变更后耐甲氧西林金黄色葡萄球菌和耐头孢他啶肺炎克雷伯菌发病率的降低
Clin Infect Dis. 1999 May;28(5):1062-6. doi: 10.1086/514743.
3
Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period.重症监护病房中的耐万古霉素肠球菌：非暴发期粪便携带率高。
Arch Intern Med. 1999 Jul 12;159(13):1467-72. doi: 10.1001/archinte.159.13.1467.
4
Risk factors for hospital-acquired Staphylococcus aureus bacteremia.医院获得性金黄色葡萄球菌菌血症的危险因素。
Arch Intern Med. 1999 Jul 12;159(13):1437-44. doi: 10.1001/archinte.159.13.1437.
5
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).新型甘氨酰环素（米诺环素的9-叔丁基甘氨酰胺衍生物，GAR-936）的体外和体内抗菌活性
Antimicrob Agents Chemother. 1999 Apr;43(4):738-44. doi: 10.1128/AAC.43.4.738.
6
Problems with antimicrobial resistance in gram-positive cocci.革兰氏阳性球菌的抗微生物耐药性问题。
Clin Infect Dis. 1998 May;26(5):1177-8. doi: 10.1086/520288.
7
Vancomycin-resistant enterococci. Mechanism and clinical relevance.耐万古霉素肠球菌。作用机制及临床意义。
Infect Dis Clin North Am. 1997 Dec;11(4):851-65. doi: 10.1016/s0891-5520(05)70393-7.
8
Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality.耐万古霉素肠球菌血症：自然病史及归因死亡率
Clin Infect Dis. 1996 Dec;23(6):1234-9. doi: 10.1093/clinids/23.6.1234.
9
Antimicrobial-drug resistance.抗菌药物耐药性
N Engl J Med. 1996 Nov 7;335(19):1445-53. doi: 10.1056/NEJM199611073351907.
10
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.注射用链阳性菌素类抗生素RP59500对耐万古霉素革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1993 Mar;37(3):598-601. doi: 10.1128/AAC.37.3.598.
Zotero 插件